.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
Healthtrust
US Army
Harvard Business School
Deloitte
Fish and Richardson
Argus Health
Teva
Farmers Insurance

Generated: July 23, 2017

DrugPatentWatch Database Preview

Celgene Company Profile

« Back to Dashboard

What is the competitive landscape for CELGENE, and what generic alternatives to CELGENE drugs are available?

CELGENE has six approved drugs.

There are fifty-one US patents protecting CELGENE drugs on CELGENE drugs in the past three years.

There are six hundred and thirty-seven patent family members on CELGENE drugs in fifty-one countries.

Summary for Applicant: Celgene

Patents:51
Tradenames:6
Ingredients:6
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene
THALOMID
thalidomide
CAPSULE;ORAL020785-003Jan 17, 2003RXYesYes6,869,399► Subscribe ► Subscribe
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880-003Jun 29, 2006RXYesNo6,281,230► Subscribe ► Subscribe
Celgene
THALOMID
thalidomide
CAPSULE;ORAL020785-003Jan 17, 2003RXYesYes7,874,984► Subscribe ► Subscribe
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880-002Dec 27, 2005RXYesNo► Subscribe► Subscribe
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880-001Dec 27, 2005RXYesNo5,635,517► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Celgene

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-003Feb 8, 20135,635,517► Subscribe
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-004Feb 8, 20136,316,471► Subscribe
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880-003Jun 29, 20066,281,230► Subscribe
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880-001Dec 27, 20056,555,554► Subscribe
Celgene
THALOMID
thalidomide
CAPSULE;ORAL020785-002Jan 17, 20037,723,361► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CELGENE drugs

Drugname Dosage Strength Tradename Submissiondate
pomalidomide
Capsules1 mg, 2 mg, 3 mg and 4 mg
POMALYST
2/8/2017
thalidomide
Capsules150 mg
THALOMID
2/3/2014
romidepsin
Injection10 mg/vial
ISTODAX
11/5/2013
lenalidomide
Capsules5 mg, 10 mg and 15 mg
REVLIMID
8/30/2010
lenalidomide
Capsules25 mg
REVLIMID
7/12/2010
thalidomide
Capsules50 mg and 100 mg
THALOMID
12/18/2006
thalidomide
Capsules200 mg
THALOMID
9/25/2006

Non-Orange Book Patents for Celgene

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,863,297Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes► Subscribe
8,093,283Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisi- noline-1,3-dione, compositions thereof, and uses thereof► Subscribe
7,459,466Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF.alpha. levels► Subscribe
8,722,647Methods for treating amyloidosis using 4-(amino)-2-(2,6-Dioxo(3-piperidyl))- isoindoline-1,3-dione► Subscribe
7,629,360Methods for the treatment of cachexia and graft v. host disease► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Celgene Drugs

Country Document Number Estimated Expiration
Portugal2046331► Subscribe
Hong Kong1083064► Subscribe
Portugal2426118► Subscribe
Canada2352629► Subscribe
CroatiaP20100664► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Celgene Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0150005 00140Estonia► SubscribePRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013
140Estonia► Subscribe
0925294/01Switzerland► SubscribePRODUCT NAME: LENALIDOMIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 57712 29.08.2007
C/GB07/047United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/047 GRANTED TO CELGENE CORPORATION IN RESPECT OF THE PRODUCT LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT , THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6228 DATED 01 OCTOBER 2008, AND THE CORRECTION OF WHICH WAS ADVERTISED IN JOURNAL NO 6523 DATED 28 MAY 2014, HAS HAD ITS MAXIMUM PERIOD OF DURATION FURTHER CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 18 JUNE 2022.
C033/2007Ireland► SubscribeSPC033/2007: 20080507, EXPIRES: 20220613
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Teva
Argus Health
Merck
Citi
Accenture
Novartis
Queensland Health
McKesson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot